Adimmune applies for human trialsBy Kao Shih-ching / Staff reporterVaccine maker Adimmune Corp (國光生技) last week applied to the Food and Drug Administration (FDA) to run phase I human clinical trials of one of its COVID-19 vaccine candidates, the company said on Monday. Although the candidate has yet to undergo full animal testing, Adimmune applied to use it in human trials under the FDA’s fast-track program for emergency use authorizations, which is intended to speed up the development of a treatment for COVID-19, it said. Adimmune hopes to start phase I human clinical trials by August, Pan said, adding that about 100 healthy volunteers are to be injected with the vaccine to see if the antigen is safe. If the phase I trials go smoothly, Adimmune plans to apply to run phase II human clinical trials by the end of this year, Pan said. “We need to test the vaccine candidate’s effectiveness in double-blind phase II clinical trials.

Source: Taipei Times June 23, 2020 15:56 UTC